EMPOWER-lung 1: A randomized, open-label, multi-national, phase III trial of cemiplimab, a human PD-1 monoclonal antibody, versus chemotherapy in first-line treatment of advanced non-small cell lung cancer (NSCLC) with PD-L1 ≥50%
Keyword(s):
Keyword(s):
Keyword(s):
2008 ◽
Vol 26
(15_suppl)
◽
pp. 8016-8016
◽
Keyword(s):
2007 ◽
Vol 5
(4)
◽
pp. 356
◽
Keyword(s):
Keyword(s):
2012 ◽
Vol 7
(9)
◽
pp. 1432-1439
◽
Keyword(s):
Keyword(s):
Keyword(s):
Keyword(s):
2008 ◽
Vol 26
(15_suppl)
◽
pp. 8017-8017
◽
Keyword(s):